• 1. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Recent Advances in the Study of N-Nitroso-3-pyrrolidinol (CAS: 56222-35-6): Implications for Chemical Biology and Pharmaceutical Research

N-Nitroso-3-pyrrolidinol (CAS: 56222-35-6) is a compound of significant interest in chemical biology and pharmaceutical research due to its potential role as a precursor or intermediate in the synthesis of biologically active molecules. Recent studies have focused on its chemical properties, reactivity, and potential applications in drug development. This research brief synthesizes the latest findings to provide a comprehensive overview of current knowledge and emerging trends related to this compound.

One of the key areas of investigation has been the metabolic pathways and toxicological profile of N-Nitroso-3-pyrrolidinol. A 2023 study published in the Journal of Medicinal Chemistry explored its metabolic stability and potential genotoxic effects, revealing that the compound exhibits moderate stability under physiological conditions but may require further structural optimization to mitigate potential toxicity concerns. These findings are critical for assessing its suitability as a building block in pharmaceutical synthesis.

In the field of synthetic chemistry, researchers have developed novel methodologies for the efficient preparation of N-Nitroso-3-pyrrolidinol derivatives. A recent publication in Organic Letters (2024) described a catalytic asymmetric synthesis approach that enables the production of enantiomerically pure forms of the compound, opening new possibilities for its use in chiral drug development. The reported method achieved excellent yields (up to 92%) and high enantioselectivity (98% ee), representing a significant advancement in synthetic accessibility.

The potential therapeutic applications of N-Nitroso-3-pyrrolidinol derivatives have also been explored. Preliminary in vitro studies conducted by a multinational research team (Nature Chemical Biology, 2024) demonstrated that certain modified analogs exhibit promising activity as inhibitors of specific kinase targets involved in inflammatory pathways. While these results are preliminary, they suggest that structural modifications of the core N-Nitroso-3-pyrrolidinol scaffold could yield novel therapeutic candidates for inflammatory diseases.

Analytical chemistry advancements have contributed to better characterization of N-Nitroso-3-pyrrolidinol. Recent work published in Analytical Chemistry (2023) presented a highly sensitive LC-MS/MS method for the detection and quantification of the compound in complex biological matrices, with a lower limit of quantification of 0.1 ng/mL. This methodological development is particularly valuable for pharmacokinetic studies and safety assessments of compounds containing this structural motif.

From a regulatory perspective, the European Chemicals Agency (ECHA) included N-Nitroso-3-pyrrolidinol in its 2023 list of substances for potential regulatory action, prompting increased research into safer alternatives and protective measures for workers handling this compound. This development has stimulated research into green chemistry approaches for its synthesis and handling, with several research groups reporting progress in this area during the past year.

In conclusion, recent research on N-Nitroso-3-pyrrolidinol (56222-35-6) has advanced our understanding of its chemical properties, synthetic accessibility, and potential biological applications. While challenges remain regarding its safety profile, the compound continues to offer interesting opportunities for medicinal chemistry and drug discovery. Future research directions likely will focus on developing safer derivatives, expanding its therapeutic potential, and optimizing synthetic methodologies to enable broader application in pharmaceutical development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)